Safety efficacy of open-label dupilumab in adult patients with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE)

被引：0
|
作者：
Thaci, D. [1 ]
Deleuran, M. [2 ]
Bissonnette, R. [3 ]
Bouaziz, J. D. [4 ]
Sun, X. [5 ]
Patel, N. [6 ]
Shumel, B. [5 ]
机构：
[1] Univ Lubeck, Lubeck, Germany
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Innovaderm Res, Montreal, PQ, Canada
[4] Hop St Louis, Paris, France
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Sanofi, Bridgewater, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 183卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P01
引用
收藏
页码：E94 / E94
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan D.
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 60 - 61
  • [22] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    Isho, Nadine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [23] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Correia, Ana Pinto
    Natalie, Chitra R.
    Pierce, Evangeline
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB84 - AB84
  • [24] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years
    Wollenberg, Andreas
    Soong, Weily
    Goooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
  • [25] Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥ 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Eichenfield, L.
    Arkwright, P. D.
    Chen, Z.
    O'Malley, J. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E115 - E116
  • [26] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Open-Label Extension (OLE) study
    Blauvelt, A.
    Wollenberg, A.
    Chen, Z.
    Bastian, M.
    Zhang, M.
    Khokhar, F. A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 66
  • [27] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [28] LONG-TERM DUPILUMAB TREATMENT IMPROVES SIGNS AND SYMPTOMS IN KOREAN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (LIBERTY AD ADULT OLE)
    Roh, Joo Young
    Park, Young Lip
    Park, Chun Wook
    Lee, Joo Hee
    Chen, Zhen
    Shumel, Brad
    Rossi, Ana B.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 53 - 53
  • [29] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [30] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Soong, W.
    Goooderham, M.
    Bissonnette, R.
    Xiao, J.
    Khokhar, F. A.
    Marco, A. R.
    Levit, N. A.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
12345